AURKA amplifications have been identified in approximately 65% of prostate adenocarcinoma that evolve into neuroendocrine tumors, including small cell, but only present in 5% of pure adenocarcinoma tumors, suggesting a potential marker or target for small cell prostate cancer or used to predict disease aggressiveness [6,10]. The gene discussed is AURKA; the disease is adenocarcinoma.